Standout Papers

Ivosidenib and Azacitidine in <i>IDH1</i> -Mutated Acute Myeloid Leukemia 2022 2026 2023 2024274
  1. Ivosidenib and Azacitidine in IDH1 -Mutated Acute Myeloid Leukemia (2022)
    Pau Montesinos, Christian Récher et al. New England Journal of Medicine

Immediate Impact

1 from Science/Nature 50 standout
Sub-graph 1 of 24

Citing Papers

The hallmarks of cancer immune evasion
2024 Standout
Targeting ROS in cancer: rationale and strategies
2024 Standout
1 intermediate paper

Works of Su‐Peng Yeh being referenced

Measurable Residual Disease Response and Prognosis in Treatment-Naïve Acute Myeloid Leukemia With Venetoclax and Azacitidine
2021

Author Peers

Author Last Decade Papers Cites
Su‐Peng Yeh 487 171 170 394 61 900
Jean‐Baptiste Micol 704 297 133 439 59 1.0k
Sarah Bertoli 762 234 209 438 64 1.0k
Danian Nie 345 120 144 286 57 741
Suzanne Tavitian 455 167 124 195 58 831
Claire Oudin 550 209 193 271 39 1.1k
Hiroshi Tsutani 426 127 156 321 77 948
Stephen Caplan 315 147 159 366 34 880
Peter Ernst 344 113 199 288 40 807
Wanzhuo Xie 456 99 209 457 77 1.1k
Dong Soon Lee 564 250 200 321 75 866

All Works

Loading papers...

Rankless by CCL
2026